Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with an investment in MinervaX
Mandate

Vinge advises Industrifonden in connection with an investment in MinervaX

December 16, 2020 Employment and Benefits Intellectual Property M&A

Vinge has advised Industrifonden in connection with its investment in MinervaX.

MinervaX has developed a vaccine against streptococcus and in connection with the financing round has procured a total of MEUR 47.4 from a syndicate consisting of Industrifonden, Sanofi Ventures, Wellington Partners and Adjuvant Capital.

Vinge’s team primarily consisted of Johan Larsson, Sara Strandberg and Stojan Arnerstål.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024